Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection

被引:17
|
作者
Axelrad, Jordan E. [1 ]
Li, Terry [2 ]
Bachour, Salam P. [3 ]
Nakamura, Takahiro, I [4 ]
Shah, Ravi [3 ]
Sachs, Michael C. [5 ]
Chang, Shannon [1 ]
Hudesman, David P. [1 ]
Holubar, Stefan D. [6 ]
Lightner, Amy L. [6 ]
Barnes, Edward L. [7 ]
Cohen, Benjamin L. [8 ]
Rieder, Florian [8 ]
Esen, Eren [9 ]
Remzi, Feza [9 ]
Regueiro, Miguel [8 ]
Click, Benjamin [8 ]
机构
[1] NYU, Dept Med, Divison Gastroenterol, Grossman Sch Med, New York, NY 10016 USA
[2] NYU, Dept Med, Grossman Sch Med, New York, NY 10016 USA
[3] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA
[4] Univ Vermont, Dept Med, Divison Gastroenterol, Larner Coll Med, Burlington, VT USA
[5] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[6] Cleveland Clin, Dept Colorectal Surg, Cleveland, OH 44106 USA
[7] UNC Sch Med, Dept Med, Div Gastroenterol, Chapel Hill, NC USA
[8] Cleveland Clin, Dept Gastroenterol Hepatol & Nutr, Cleveland, OH 44106 USA
[9] NYU, Dept Surg, Grossman Sch Med, New York, NY 10016 USA
关键词
Crohn's disease; postoperative recurrence; resection; biologic therapy; MAGNETIC-RESONANCE ENTEROGRAPHY; COMPUTED-TOMOGRAPHY; ILEOCOLIC RESECTION; METAANALYSIS; ADALIMUMAB; RISK; PREVENTION; MANAGEMENT;
D O I
10.1093/ibd/izac158
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Lay Summary Postoperative recurrence of Crohn's disease is common after ileocecal resection. In this dual-center study, early initiation of an anti-TNF agent within 4 weeks following an ileocecal resection was associated with a reduction in postoperative recurrence of Crohn's disease. Background Postoperative recurrence (POR) of Crohn's disease (CD) is common after surgical resection. We aimed to compare biologic type and timing for preventing POR in adult CD patients after ileocecal resection (ICR). Methods We performed a retrospective cohort study of CD patients who underwent an ICR at 2 medical centers. Recurrence was defined by endoscopy (>= i2b Rutgeerts score) or radiography (active inflammation in neoterminal ileum) and stratified by type and timing of postoperative prophylactic biologic within 12 weeks following an ICR (none, tumor necrosis factor antagonists [anti-TNF], vedolizumab, and ustekinumab). Results We identified 1037 patients with CD who underwent an ICR. Of 278 (26%) who received postoperative prophylaxis, 80% were placed on an anti-TNF agent (n = 223) followed by ustekinumab (n = 28, 10%) and vedolizumab (n = 27, 10%). Prophylaxis was initiated in 35% within 4 weeks following an ICR and in 65% within 4 to 12 weeks. After adjusting for factors associated with POR, compared with no biologic prophylaxis, the initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR (adjusted hazard ratio, 0.61; 95% CI, 0.40-0.93). Prophylaxis after 4 weeks following an ICR or with vedolizumab or ustekinumab was not associated with a reduction in POR compared with those who did not receive prophylaxis. Conclusion Early initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR. Vedolizumab or ustekinumab, at any time following surgery, was not associated with a reduction in POR, although sample size was limited.
引用
收藏
页码:888 / 897
页数:10
相关论文
共 50 条
  • [1] EARLY INITIATION OF ANTI-TUMOR NECROSIS FACTOR THERAPY REDUCES POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE FOLLOWING ILEOCECAL RESECTION
    Axelrad, Jordan E.
    Li, Terry
    Nakamura, Takahiro
    Bachour, Salam P.
    Shah, Ravi S.
    Sachs, Michael
    Chang, Shannon
    Hudesman, David
    Holubar, Stefan D.
    Cohen, Benjamin L.
    Rieder, Florian
    Lightner, Amy L.
    Esen, Eren
    Barnes, Edward L.
    Remzi, Feza H.
    Regueiro, Miguel D.
    Click, Benjamin
    GASTROENTEROLOGY, 2022, 162 (07) : S183 - S184
  • [2] Optimal biologic management of endoscopic postoperative recurrence following ileocecal resection in Crohn's disease
    Bachour, S.
    Shah, R.
    Lyu, R.
    Rieder, F.
    Cohen, B.
    Qazi, T.
    Lashner, B.
    Achkar, J. P.
    Philpott, J.
    Lightner, A.
    Holubar, S.
    Regueiro, M.
    Click, B.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S529 - S531
  • [3] Risk factors of postoperative recurrence after ileocecal resection for Crohn's disease
    Said, Y.
    Dabbabi, A.
    Bettaieb, J.
    Trabelsi, S.
    Debbeche, R.
    Bouzaidi, S.
    Salem, M.
    Zaouche, A.
    Dziri, C.
    Najjar, T.
    JOURNAL AFRICAIN D HEPATO-GASTROENTEROLOGIE, 2011, 5 (03): : 198 - 204
  • [4] Early Ileocecal Resection Is an Effective Therapy in Isolated Crohn's Disease
    Kelm, Matthias
    Anger, Friedrich
    Eichlinger, Robin
    Brand, Markus
    Kim, Mia
    Reibetanz, Joachim
    Krajinovic, Katica
    Germer, Christoph-Thomas
    Schlegel, Nicolas
    Flemming, Sven
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (04) : 1 - 12
  • [5] Antitumor necrosis factor-α therapy for early postoperative recurrence of gastrointestinal Behcet's disease:: Report of a case
    Byeon, Jeong-Sik
    Choi, Eun Kwang
    Heo, Nae Yun
    Hong, Seok Chan
    Myung, Seung-Jae
    Yang, Suk-Kyun
    Kim, Jin-Ho
    Song, Jae-Kwan
    Yoo, Bin
    Yu, Chang Sik
    DISEASES OF THE COLON & RECTUM, 2007, 50 (05) : 672 - 676
  • [6] Abdominal phlegmons in Crohn's disease: Outcomes following antitumor necrosis factor therapy
    Cullen, Garret
    Vaughn, Byron
    Ahmed, Awais
    Peppercorn, Mark A.
    Smith, Martin P.
    Moss, Alan C.
    Cheifetz, Adam S.
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (04) : 691 - 696
  • [7] POSTOPERATIVE CROHN'S DISEASE RECURRENCE RISK AND OPTIMAL BIOLOGIC TIMING AFTER TEMPORARY DIVERSION FOLLOWING ILEOCECAL RESECTION
    Joseph, Abel
    Bachour, Salam P.
    Shah, Ravi S.
    El Halabi, Jessica
    Cohen, Benjamin L.
    Rieder, Florian
    Achkar, Jean-Paul
    Philpott, Jessica
    Qazi, Taha
    Lightner, Amy L.
    Hull, Tracy L.
    Lipman, Jeremy M.
    Holubar, Stefan D.
    Regueiro, Miguel D.
    Click, Benjamin
    GASTROENTEROLOGY, 2022, 162 (07) : S183 - S183
  • [8] Children with Localized Crohn's Disease Benefit from Early Ileocecal Resection and Perioperative Anti-Tumor Necrosis Factor Therapy
    Weigl, Elena
    Schwerd, Tobias
    Lurz, Eberhard
    Haeberle, Beate
    Koletzko, Sibylle
    Hubertus, Jochen
    EUROPEAN JOURNAL OF PEDIATRIC SURGERY, 2023, : 236 - 244
  • [9] MUCOSAL RECOLONIZATION AFTER ILEOCECAL RESECTION DIFFERS IN CROHN'S DISEASE PATIENTS DEVELOPING POSTOPERATIVE RECURRENCE
    Machiels, Kathleen
    del Rio, Marta Pozuelo
    Sabino, Joao
    Santiago, Alba
    Campos, David
    Wolthuis, Albert
    van Overstraeten, Anthony de Buck
    D'Hoore, Andre
    Van Assche, Gert A.
    Ferrante, Marc
    Rutgeerts, Paul
    De Hertogh, Gert
    Vermeire, Severine
    Manichanh, Chaysavanh
    GASTROENTEROLOGY, 2017, 152 (05) : S990 - S990
  • [10] Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation
    Beilman, Candace L.
    Kirwin, Erin
    Ma, Christopher
    McCabe, Christopher
    Fedorak, Richard N.
    Halloran, Brendan
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (08) : 1515 - +